Patents by Inventor Ronald J. Koenig

Ronald J. Koenig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6528059
    Abstract: Specific epitopic regions of thyroid peroxidase (TPO), a thyroid specific membrane autoantigen, have been identified within amino acid residues 456 to 933, 457 to 633, 513 to 633, and 633 to 933 of the protein (SEQ ID NO:2), with at least one distinct binding region within TPO located from amino acid residues 592 to 613 (SEQ ID NO:7). The identification and production of these localized epitopes/epitopic regions provide specific therapeutic reagents for administration to autoimmune thyroid disease patients.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: March 4, 2003
    Assignee: Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Ronald J. Koenig
  • Patent number: 5998153
    Abstract: Specific epitopic regions of thyroid peroxidase (TPO), a thyroid specific membrane autoantigen, have been identified within amino acid residues 456 to 933, 517 to 630, and 633 to 933 of the protein (SEQ ID NO:1), with at least one distinct binding region within TPO located from amino acid residues 592 to 613 (SEQ ID NO:3). The identification and production of these localized epitopes/epitopic regions provide specific diagnostic reagents for autoimmune thyroid disease.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: December 7, 1999
    Assignee: The Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Ronald J. Koenig
  • Patent number: 4247533
    Abstract: Sheep antiserum developed against the human glycohemoglobin, Hb A.sub.1c, distinguishes this fraction from the major component Hb A.sub.o. Partial cross relativity is observed with Hb A.sub.1a and Hb A.sub.1b, as well as with analogous glycohemoglobins from mouse and dog hemolysates. The reactivity of the hemoglobins with this specific antiserum is abolished by the reduction of the keto group of the sugar ligand. The immunological specificity displayed provides the basis of a quantitative assay for Hb A.sub.1c, which is suitable for studies of clinical and experimental diabetes.
    Type: Grant
    Filed: May 1, 1978
    Date of Patent: January 27, 1981
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Ronald J. Koenig, Jamshid Javid, Penelope K. Pettis